Medindia LOGIN REGISTER
Medindia
Advertisement

ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver

Tuesday, September 30, 2008 General News
Advertisement
ADDISON, Texas, Sept. 30 ULURU Inc. (Amex: ULU)today announced that it has filed a 510k application with the United StatesFood and Drug Administration (FDA) for Altrazeal(TM) Silver.
Advertisement

Preclinical studies conducted to support the filing have shown thatsuperior healing rates in numerous porcine wound models have been achievedrelative to competitive silver dressings. Additionally, in toxicology and invitro bacteria inhibition studies Altrazeal(TM) Silver has performed favorablyrelative to competitive silver dressings. This data should favorably positionAltrazeal(TM) Silver in the market, providing benefits to both the patient andthe health care provider.
Advertisement

The use of silver in wound care is increasing rapidly in the management ofinfected wounds and wounds at risk for infection. Silver has been usedextensively as a broad-spectrum antimicrobial particularly in the treatment ofchronic wounds and to manage burn infections. Wounds exhibiting increasedbacterial burden have reduced healing responses when compared to woundscontaining fewer bacteria.

Commenting on the 510k filing, Kerry P. Gray, President and CEO of ULURUInc. stated, "This is an important milestone in the development of our woundcare franchise. In certain wound types silver-containing products are usedextensively by physicians. We have responded to a market need by developingAltrazael(TM) Silver as our sales organization has received consistentfeedback from wound care practitioners that a silver containing Altrazeal(TM)is one of the products that would improve wound treatment. We expect to launchAltazeal(TM) Silver in the first quarter 2009."

In addition to being a superior wound dressing Altrazeal(TM), whichincorporates our Nanoflex(TM) technology, is also a controlled drug deliverytechnology enabling active wound healing agents to be delivered to the woundbed over periods of up to 30 days. Altrazeal(TM) Silver is the first in aseries of planned line extensions designed to improve the treatment of bothacute and chronic wounds. The company strategy is to develop additionalAltrazeal(TM) products incorporating active compounds for the treatment of thevarious phases of wound healing, infection, inflammation, debridement,maturation and closure. By implementing this strategy we believe that we willbe delivering the products necessary to significantly improve wound healing.

Gray continued, "Our objective is to transform wound healing from"dressing a wound" to "treating a wound" by providing a range of products forthe various phases of wound healing. The initial clinical data onAltrazeal(TM) which will be presented at an upcoming wound conference in LasVegas at the end of October is very exciting. Time to healing in numerouschronic, acute and traumatic wounds is significantly shorter than physicianshave previously experienced. We believe that we can further improve woundtreatment with our planned introduction of actives in the Altrazeal(TM)dressing."

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on thedevelopment of a portfolio of wound management, plastic surgery and oral careproducts to provide patients and consumers improved clinical outcomes throughcontrolled delivery utilizing its innovative transmucosal delivery system andNanoflex(TM) Aggregate technology. For further information about ULURU Inc.,please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-lookingwithin the meaning of Section 27a of the Securities Act of 1933, as amended,including but not limited to statements made relating to the response to theproduct from physicians and nurses, the importance of use of the product forburn victims, the ability to use the product for chronic wounds, theperception of the product as a transformational innovation in the wound caremarket, our plan to add two products to our wound care franchise in 2009, anda product launch in the first quarter of 2009. These statements are subject tonumerous risks and uncertainties, including but not limited to the riskfactors detailed in the Company's Annual Report on Form 10-KSB for the yearended December 31, 2007, Quarterly Report on Form 10-Q for the quarter endedJune 30, 2008 and other reports filed by us with the Securities and ExchangeCommission.Contact: Company Kerry P. Gray President & CEO Terry K. Wallberg Vice President & CFO (214) 905-5145

SOURCE ULURU Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close